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Abstract
We report two female patients with focal segmental glomerulosclerosis and chronic kidney disease. The first patient
was found to have a heterozygous, de novo, pathogenic variant in COL4A5 (c.141+1G>A, IVS2+1G>A), which is
associated with Alport syndrome. The second patient was found to have a heterozygous, likely pathogenic variant in
COL4A4 (c.2842G>T). Both these variants in COL4A5 and COL4A4 are novel, and they were detected using whole exome
sequencing and gene panel testing, respectively. Additionally, we discuss the complexities of diagnosis in such cases
and the benefits of using the abovementioned diagnostic approaches.
Introduction
Focal segmental glomerulosclerosis (FSGS) is a pro-
gressive kidney disease that can be either a primary renal
disorder or secondary due to other etiologies, including
genetic etiologies1. It is the culprit of approximately 40% of
nephrotic syndrome cases in adults and 20% in children2, 3.
As the name suggests, FSGS is characterized by focal [less
than 50% of glomeruli are affected in light microscopy
(LM)] and segmental [less than 50% of a glomerular tuft is
affected] glomerular sclerosis and by varying degrees of
foot process effacement2. Pathogenic variants in genes
that are specific to the function and structure of podo-
cytes, such as TRPC6, ACTN4, WT1, CD2AP, INF2,
NPHS2, and PLCE1, have been reported to cause familial
FSGS4. Pathogenic variants in collagen type IV genes
(COL4A3, COL4A4, and COL4A5) are related to a spec-
trum of disorders with heterogeneous clinical
manifestations.
Alport syndrome (AS), which is caused by glomerular
membrane defects, has X-linked and autosomal
dominant/recessive modes of inheritance. Classical AS
has X-linked inheritance due to pathogenic variants in
COL4A5 (86% of cases) and usually presents in early
childhood with microscopic or gross hematuria, which
progresses to end stage renal disease5.The remaining 15%
of AS has autosomal inheritance and is thought to be due
to pathogenic variants in the COL4A3 and COL4A4 genes.
Thin basement membrane nephropathy (TBMN), which
is also characterized by glomerular membrane abnorm-
alities, has been linked to COL4A3 and COL4A4 as well6.
Renal disorders causing glomerular basement membrane
structural abnormalities are known collectively as col-
lagen IV nephropathies (COL4Ns)7. FSGS typically pre-
sents with proteinuria, often in the nephrotic range, which
progresses over months to years to a reduction in glo-
merular filtration rate (GFR). COL4A3 and COL4A4,
which are located on chromosome 2, have been associated
with FSGS8. Herein, we present two families with novel
COL4A4 and COL4A5 variants diagnosed by massively
parallel exome sequencing and discuss the complexities of
managing these genetic results.
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Materials and methods
To identify the molecular bases of the patients’ pheno-
types, whole exome sequencing was utilized in the first
patient, while the second proband was tested with a
nephrotic syndrome/focal segmental glomerulosclerosis
sequencing panel.
Results
The exome sequencing revealed a heterozygous, de
novo, pathogenic variant in COL4A5 (c.141+1G>A,
IVS2+1G>A), a heterozygous, paternally inherited,
pathogenic variant in ABCA4 (c.2588G>C, p.G863A) and
a heterozygous, maternally inherited, likely pathogenic
variant in ABCA4 (c.203C>G, p.P68R). The nephrotic
syndrome/focal segmental glomerulosclerosis sequencing
panel detected a heterozygous, likely pathogenic variant in
COL4A4 (c.2842G>T).
Family 1
Our first proband is a 52-year-old female with stage IV
chronic kidney disease (estimated GFR of 28.2 mL/min),
microalbuminuria (microalbumin/creatinine ratio of
206 mg/g) and microscopic hematuria. Her kidney dis-
ease first started at age 7, when she presented with
microscopic hematuria, which was thought to be benign.
At that point in time, her kidney function was normal,
and she subsequently did well until age 34, when she
developed proteinuria (3 grams of protein/24-h urine),
hypertension and creatinine clearance of 45 mL/min.
She underwent a renal biopsy, which showed FSGS with
no foot process effacement, suggestive of a secondary
form. She was started on 30 mg prednisone daily, which
resulted in remission of her proteinuria. A renal ultra-
sound scan showed multiple bilateral renal cysts (Fig. 1),
though no family history of ADPKD was found. How-
ever, her son was also diagnosed with microscopic
hematuria at age 7. In addition to the kidney disease, the
patient has chronic arthritis, for which she takes low-
dose prednisone; hypermobile joints; migraine head-
aches; and macular degeneration, which was diagnosed
at age 40. She underwent a brain MRI to evaluate the
headaches, and the result was normal except for a mild
Chiari malformation. A genetic etiology to her kidney
disease was suspected, and samples from the proband’s
mother, father and affected son were submitted for
variant segregation analysis by whole exome sequencing
(WES). The patient was found to have a heterozygous,
de novo, pathogenic variant in COL4A5 (c.141+1G>A,
IVS2+1G>A), which is associated with Alport syn-
drome. As it is de novo, her siblings are unlikely to be at
risk for the disorder, although germline mosaicism
cannot be excluded. Her son (18 years of age) carries
this variant, giving him the genetic diagnosis of Alport
syndrome as well. Moreover, the patient was found to be
a compound heterozygote for ABCA4 variants. She has a
heterozygous, paternally inherited, pathogenic variant in
ABCA4 (c.2588G>C, p.G863A) and a heterozygous,
maternally inherited, likely pathogenic variant in
ABCA4 (c.203 C >G, p.P68R). These variants likely are
the cause for the patient’s macular degeneration and
vision loss.
Family 2
Our second proband is a 48-year-old female with stage
IV chronic kidney disease (estimated GFR of 22.5 mL/
min), nephrotic syndrome (6 g of protein/24-h urine) and
hypertension. She underwent a renal biopsy, which
revealed FSGS with patchy moderate tubular atrophy,
interstitial fibrosis and mild chronic inflammation. She
was initially started on prednisone but did not tolerate it
due to excessive weight gain of up to 60 pounds and
dyspnea. Her renal condition was treated with a combi-
nation of ACE inhibitor and ARB medications and
excellent blood pressure control, which decreased her
proteinuria to 250mg/24-h urine. Subsequently, her
proteinuria started increasing again, and she was started
on tacrolimus but showed poor response. She has a his-
tory of endometrial adenocarcinoma and endometrioid
ovarian carcinoma. The patient also has a history of
Fig. 1 Renal ultrasound showing multiple bilateral cysts
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hypertension and obesity, as well as a family history of
cancer (Fig. 2). The proband’s mother and two sons have
hematuria. The patient’s sister carried a diagnosis of FSGS
and stage IV chronic kidney disease (estimated GFR of
24mL/min); her brother passed away at age 49 due to
cardiac disease and was noted to have had hearing loss at
a young age. Our proband was tested with a nephrotic
syndrome/focal segmental glomerulosclerosis sequencing
panel (Table 1). She was found to have a heterozygous,
likely pathogenic variant in COL4A4 (c.2842G>T).
Discussion
Type IV collagen-related nephropathy, in which there
is disruption of the normal glomerular basement
membrane architecture and kidney disease, has been
linked to pathogenic variants in COL4A3, COL4A4, and
COL4A59. Heterozygous mutations in COL4A3 and
COL4A4 result in mild disease with or without isolated
microscopic hematuria (MH) characterized by focal or
diffuse thinning of the GBM, which is called thin base-
ment membrane nephropathy (TBMN)9. Males hemi-
zygous for COL4A5 pathogenic variants, and individuals
of either sex with homozygous or compound hetero-
zygous COL4A3/4 pathogenic variants, are at a greater
risk of developing X-linked and autosomal recessive
Alport syndrome, respectively10. ESRD develops within
the first three decades of life in AS, which is also
associated with sensorineural deafness and ocular
abnormalities, including asymptomatic dot and fleck
retinopathy and lenticonus11,12. Females with hetero-
zygous pathogenic variants in COL4A5 can present a
variety of clinical features ranging from asymptomatic
hematuria to more severe disease with progression to
ESRD13. Moreover, pathogenic mutations in COL4A5
have been identified in families with familial and
sporadic FSGS14. The presence of bilateral renal cysts in
our patient is interesting, as, to the best of our knowl-
edge, an association between COL4A5 variants and renal
cysts has not been reported before.
In our first proband, WES detected a heterozygous
variant in COL4A5 (c.141+1G>A, IVS2+1G>A). To the
best of our knowledge, this variant has not been
reported previously as either a pathogenic or a benign
variant. This splice site variant destroys the canonical
splice donor site in intron 2 and is predicted to cause
abnormal gene splicing. The c.141+1G>A variant has
not been not observed in large population cohorts15–17.
Based on the ACMG 2015 guidelines, the c c.141+1G>A,
IVS2+1G>A variant was classified as a pathogenic var-
iant18. Even though our second proband had diffuse foot
process effacement, her poor response to immunosup-
pression raised suspicion of a genetic etiology19. She was
tested with a nephrotic syndrome/focal segmental glo-
merulosclerosis sequencing panel, which detected a
Fig. 2 Family 2 pedigree. The proband is indicated with an arrow head
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heterozygous and likely pathogenic variant in COL4A4
(c.2842G>T). This variant is predicted to result in a pre-
mature protein termination (p.Gly948). This variant alone
is probably sufficient to be the primary cause of the renal
disease in this patient. Notably, heterozygous missense
variants in COL4A4 and COL4A3 have been reported to
cause familial or sporadic FSGS18,20.
While the first patient underwent WES, which detected
a pathogenic variant in COL4A5, the second patient had a
nephrotic syndrome/focal segmental glomerulosclerosis
sequencing panel that revealed a likely pathogenic variant
in COL4A4. There is an ongoing debate between the
advantages and drawbacks of each test, especially in
Mendelian disorders. One advantage of WES is variant
segregation analysis and the concurrent testing of other
family members, which can identify the pattern of Men-
delian inheritance and detect other incidental variants
that can be of clinical significance. Our first proband,
thanks to WES, was found to be compound heterozygous
for two ABCA4 variants. This finding helps in explaining
her macular degeneration and vision loss and would be of
great value when counseling this patient and her family.
Gene panels have historically been preferred, especially
when looking for genes related to a patient’s phenotype,
because of their low cost and short turnaround time, and
many clinical geneticists consider them a rapid first-tier
test.
Molecular genetic testing is noninvasive, can be highly
accurate and is becoming the diagnostic procedure of
choice for Alport syndrome since renal pathology findings
of FSGS do not necessarily indicate genetic mutation21.
Therefore, a multidisciplinary team approach, with
expertize in clinical genetics, nephrology, and nephro-
pathology, is important to attain an accurate diagnosis.
While the rate of progression of renal disease may be
related to the underlying causal mutation, molecular
analysis may eventually provide more prognostic data
than either renal or skin biopsy. Massively parallel (next
generation) sequencing allows simultaneous analysis of
the COL4A3, COL4A4, and COL4A5 genes, providing
benefits in screening time and cost, and should be con-
sidered in similar cases to ours22,23. In summary, we
present two families with novel pathogenic variants in
COL4A5 and COL4A4 diagnosed by exome sequencing
Table 1 Nephrotic syndrome/focal segmental
glomerulosclerosis sequencing panel
Gene OMIM ID
ACTN4 604638
ANLN 616027
ARHGAP24 610586
ARHGDIA 601925
CD2AP 604241
COL4A3 120070
COL4A4 120131
COL4A5 303630
COL4A6 303631
COQ2 609825
COQ6 614647
COQ8B 615567
CRB2 609720
CUBN 602997
DGKE 601440
EMP2 602334
FAT1 600976
INF2 610982
ITGA3 605025
ITGB4 147557
KANK1 607704
KANK2 614610
KANK4 614612
LAMB2 150325
LMX1B 602575
MYO1E 601479
NEIL1 608844
NEXMIF 300524
NPHS1 602716
NPHS2 604766
NUP107 607617
NUP205 614352
NUP93 614351
PAX2 167409
PDSS2 610564
PLCE1 608414
PTPRO 600579
SCARB2 602257
SMARCAL1 606622
Table 1 continued
Gene OMIM ID
TRPC6 603652
TTC21B 612014
WDR73 616144
WT1 607102
XPO5 607845
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and gene panel testing, respectively, and discuss the
merits of these approaches.
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